Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Biocartis  /  Biocartis forum geopend

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Biocartis BRU:BCART.BL, BE0974281132

  • 0,290 22 sep 2023
  • 0,000 (0,00%) Dagrange 0,000 - 0,000
  • 0

Biocartis forum geopend

6.444 Posts
Pagina: «« 1 ... 47 48 49 50 51 ... 323 »» | Laatste | Omlaag ↓
  1. Flatlander 10 september 2019 16:32
    To date, the only FDA approvals in the US have come largely through the efforts of JnJ. The 2017 console, and the RSV cartridge approval were largely JnJs doing. The RSV cartridge was apparently rendered obsolete by competing devices and Biocartis decided to exit the infectious disease market.. I took the 2018 announcement that Biocartis was opening a facility in the JnJ space in Raratan NJ and acquiring 10 JnJ staff as a sign that they would tap JnJ strengths to expedite winning regulatory approvals. This has not been evident. My concern now is that JnJ may looking to acquire BCART on the cheap. If BCART continues on this trajectory the they may need to raise cash again in late 2020 or early 2021. This will be difficult unless the outlook changes. As I mentioned previously, there are many catalysts that can change the trajectory for the better, but the execution needs to improve.

    There is still a lot of time. Rather than emphasizing the buildup of a US sales force (an expensive proposition), I think BCART needs to emphasize regulatory approvals that will make Idylla eligible for insurance reimbursement. With regulatory approvals, their partners will help sell and they can avoid the advertisement restrictions that are currently constraining marketing in the US.

    FL
  2. Flatlander 10 september 2019 16:48
    Don't want to come across too negative.but history is littered with companies that brought new technology to market only to have someone else succeed in making it commercially successful (think about the commodore PC). The pathology journals I have read indicate strong support for first line use of Idylla but the business execution does not appear to be capitalizing on this potential. As I've indicated from my experience with GHDX, it can take a while before a critical mass of support is developed that allows commercial traction possible. The partnerships and the technical seminar presentations (especially user testimonials) are critical in developing this support.

    FL
  3. ronald64 11 september 2019 07:00
    quote:

    makyjo schreef op 10 september 2019 16:24:

    Ideaal om NU bij te kopen.
    Alleen voor de durvers!!
    Want is zeker een andere verhaal dan Thrombogenics. (Oxurion)
    Biocartis berichtte vorige week woensdag over een halvering van de oorspronkelijke groeiprognoses. Vorige week woensdag noteerde het aandeel vlak voor de domper nog € 10,28. De groeibijstelling leidde donderdag tot een vrije val naar € 6,98. Zojuist werd € 6,50 op het koersenbord gesignaleerd. De koershistorie van Biocartis toont in 2016 een bodemproces tussen € 6,69 en € 6,59. De relatieve sterkte index raakte vorige week het meest oversold in relatie tot voorgaande oververkochte waarderingen. Traders die zich afvragen wat te doen in deze overwegend afwachtende markt weten dat de beste koopmomenten zich voordoen als het spreekwoordelijke bloed door de straat loopt.
  6. Look0406 13 september 2019 11:51
    quote:

    ronald64 schreef op 11 september 2019 07:00:

    [...]

    Biocartis berichtte vorige week woensdag over een halvering van de oorspronkelijke groeiprognoses. Vorige week woensdag noteerde het aandeel vlak voor de domper nog € 10,28. De groeibijstelling leidde donderdag tot een vrije val naar € 6,98. Zojuist werd € 6,50 op het koersenbord gesignaleerd. De koershistorie van Biocartis toont in 2016 een bodemproces tussen € 6,69 en € 6,59. De relatieve sterkte index raakte vorige week het meest oversold in relatie tot voorgaande oververkochte waarderingen. Traders die zich afvragen wat te doen in deze overwegend afwachtende markt weten dat de beste koopmomenten zich voordoen als het spreekwoordelijke bloed door de straat loopt.
    Aldus Loef.
    Inderdaad mooi koopmoment, iedereen die er uit wilde is eruit.
  10. Flatlander 17 september 2019 07:09
    www.fishersci.com/us/en/catalog/searc...

    The situation with Fisher in the US has become pretty transparent. They continue to market the consoles on the Fisher platform but not the cartridges. The console has received a determination that it is exempted from FDA 510K approval process. But the assay cartridges are approved in the US for research use only RUO designation..

    www.globenewswire.com/news-release/20...

    Trading of Biocartis on the Schwab global platform is suspended on a regulatory violation (SEC Regulation S), This regulation limits the advertising statements that can be made about a product until it has secured approvals. Putting 2+2 together, it is apparent that it is likely that Fisher overstepped the advertising limitation that can be made under the RUO designation. Hence, they can no longer sell the cartridges on the Fisher exchange site.

    I believe the cartridges came off of the exchange in early July explaining the big US sales miss. I think BCART had no other choice but to internalize the sales so they can strictly control the promotional materials and the sales pitch. This can be corrected with FDA 510K approval of the assay cartridges.

    The good news is that if a product is truly an advancement, it can be very successful even if it stumbles in the U.S. Possibly due to no fault of its own. I've invested in Novartis for a long time. They brought a diabetes drug called Galvus to the FDA for approval and it got rejected on concerns over early animal testing rashes during the preclinical trials. This happened despite one of the largest Phase III studies ever conducted at the time bearing out the efficacy and the lack of this drug side effect. Galvus went on to become a blockbuster with approvals throughout the world but it never came to market in the US. NVS saw the writing on the wall and withdrew the FDA approval application and never refiled despite the US market being the largest diabetes market in the world.. This opened the door for Merk's competing drug Januvia. My point is that regulatory powers are often applied in ways that are designed to benefit domestic competitors.. Unfortunately it happens throughout the world. However, if the product is a true advancement, it can still do great even with trade barriers that might create temporary stumbles. It is critical to recognize the nature of the impediments and to determine how to best allocate resources given the impediments. The right partners can also make all the difference in gaining regulatory approvals.

    FL

  15. Flatlander 24 september 2019 19:09
    Tomorrow's meeting and the turmoil since the Sept 5 earnings announcement will result in some shakeup in the shareholder base. I expect that some consolidation is occurring as some smaller holders are getting shaken out. The shareholder base is currently widely disseminated such that it would be difficult to acquire BCART without wide shareholder support. Consolidation will reduce the number of holders, such that an acquisition might be easier in the future. I'm not saying anything is imminent, only that the dynamics are likely to be changing.

    FL

6.444 Posts
Pagina: «« 1 ... 47 48 49 50 51 ... 323 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!